IMR Press / EJGO / Volume 28 / Issue 5 / pii/2007184

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Original Research

Radiation reduces carboplatin sensitivity and enhances nedaplatin sensitivity in cervical squamous cell carcinoma in vitro

Show Less
1 Department of Obstetrics and Gynecology, Wakayama Medical University, Wakayama, Japan
2 Department of Physiology, Wakayama Medical University, Wakayama, Japan
Eur. J. Gynaecol. Oncol. 2007, 28(5), 352–355;
Published: 10 October 2007

Background: The study was performed to examine how the platinum anticancer drugs other than cisplatin, such as carboplatin (CBDCA) and nedaplatin (NEP) can be effectively used in chemoradiotherapy for cervical squamous cell carcinoma patients. Materials and Methods: The radiosensitive human cervical squamous cell carcinoma cell line ME 180 was examined to investi­gate the radiation effects on CBDCA and NEP sensitivities of the cells. Results: Irradiation significantly reduced cellular CBDCA sensitivity. There were no significant changes in CBDCA sensitivity between the cells concurrently irradiated and those treated with CBDCA 8 h before or 8 h after irradiation. However NEP sensi­tivity of the cells treated 8 h before or 8 h after irradiation was significantly higher than that in cells concurrently irradiated. Conclusions: Although CBDCA sensitivity in the concurrently irradiated cells is reduced, NEP sensitivity is enhanced by irradiation. NEP, but not CBDCA, therefore, may be a candidate anticancer drug for concurrent chemoradiotherapy for cervical cancer. For the greatest efficacy, NEP should be administered to patients several hours before or after irradiation.

Cervical cancer
Squamous cell carcinoma
Back to top